Brief: Immixbio Ships Tislelizumab For Patient Dosing In Its Combination Clinical Trial With Imx-110 In Advanced Solid Tumors
19/12/2022 13:04
Dec 19 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIXBIO SHIPS TISLELIZUMAB FOR PATIENT DOSING IN ITS
COMBINATION CLINICAL TRIAL WITH IMX-110 IN ADVANCED SOLID TUMORS
* IMX-110 + TISLELIZUMAB CLINICAL TRIAL DATA EXPECTED TO BE
RELEASED ON A ROLLING BASIS BEGINNING IN Q1 2023
Source text for Eikon: ID:nGNEbttcRF
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary